# DESCRIPTION

## FIELD OF THE INVENTION

- define field of invention

## BACKGROUND

- discuss atherosclerosis and PCSK9

## BRIEF SUMMARY OF THE INVENTION

- introduce therapeutic methods
- describe administration of PCSK9 inhibitor
- provide pharmaceutical composition
- treat or inhibit atherosclerosis
- treat nonhyperlipidemic subjects
- provide various embodiments

## DETAILED DESCRIPTION

- define scope and terminology

### Methods for Inhibiting Atherosclerosis

- identify subjects at risk of atherosclerosis
- administer PCSK9 inhibitor to selected subjects
- define nonhyperlipidemic and apparently healthy subjects
- describe subjects with previous cardiovascular events or diseases
- identify subjects with elevated inflammatory markers

### PCSK9 Inhibitors

- define PCSK9 inhibitor
- describe categories of PCSK9 inhibitors
- define PCSK9
- describe administration of PCSK9 inhibitor
- describe reduction of atherosclerotic plaque formation
- define antibody
- describe structure of antibody
- describe antigen-binding fragments of antibody
- describe non-limiting examples of antigen-binding fragments
- describe configuration of variable and constant domains
- describe hinge region
- describe multispecific antigen-binding fragments
- describe importance of constant region
- define human antibody
- define recombinant human antibody
- describe isolated antibody
- define specifically binds
- describe exemplary PCSK9 inhibitors
- describe germline mutations
- describe conservative substitutions
- define surface plasmon resonance
- define epitope

### Preparation of Human Antibodies

- introduce VELOCIMMUNE technology
- generate transgenic mouse with human variable regions
- challenge mouse with antigen and recover lymphatic cells
- fuse lymphatic cells with myeloma cell line
- screen and select hybridoma cell lines
- isolate DNA encoding variable regions
- link DNA to human constant regions
- produce antibody protein in cell
- characterize and select antibodies
- replace mouse constant regions with human constant regions
- describe specific examples of human antibodies
- describe properties of antibodies when administered to mice

### Pharmaceutical Compositions and Methods of Administration

- formulate PCSK9 inhibitor with carriers and excipients
- describe various delivery systems
- list methods of administration
- describe pen delivery devices and autoinjector delivery devices
- describe reusable and disposable delivery devices
- describe controlled release systems
- describe injectable preparations
- describe unit dosage forms and articles of manufacture

### Dosage and Administration Regimens

- define therapeutically effective amount
- specify dosage range of anti-PCSK9 antibody
- describe administration of multiple doses
- define initial, secondary, and tertiary doses
- specify frequency of secondary and tertiary doses
- provide examples of administration regimens
- describe monitoring and adjustment of dosage

### Prior Therapies and Combination Therapies

- describe administration with prior therapies
- describe administration as monotherapy or combination therapy

## EXAMPLES

- provide examples of invention

### Example 1

- generate human antibodies to PCSK9

### Example 2

- study attainment of LDL-C goals in patients at high cardiovascular risk

### Example 3

- study LDL-C goal attainment and lipid-lowering therapy in high cardiovascular risk population

### Example 4

- introduce study objective
- describe animal model
- outline experimental design
- detail diet and treatment regimens
- describe plasma lipid and lipoprotein analysis
- outline measurement of MAb316P levels
- describe hepatic LDLR protein analysis
- detail histological assessment of atherosclerosis
- describe hepatic lipid analysis
- outline fecal excretion of bile acids and neutral sterols
- describe flow cytometric analysis
- outline statistical analysis
- present results of plasma lipid and lipoprotein analysis
- present results of hepatic LDLR protein analysis
- present results of atherosclerosis development
- present results of lesion composition analysis
- present results of monocyte and T-cell recruitment
- present results of lesion stability index
- present results of circulating monocyte analysis

## SUMMARY

- summarize study results

